incidence Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and eighth most common cancer in women worldwide. Its crude incidence in the European Union is 8.29/ 100 000. It is four to eight times more common in men and usually associated with chronic liver injury (hepatitis B, hepatitis C and alchocolic cirrhosis). Median age at diagnosis is between 50 and 60 years.
diagnosis
Diagnosis is usually made by history, physical examination, imaging (ultrasound, MRI or CT scan showing a liver mass consistent with HCC) and elevated serum a-fetoprotein (AFP 400 ng/ml). Confirmation of diagnosis is made by fine needle aspiration or biopsy. Elevation of AFP >400 ng/ml can be used instead of fine needle cytology for diagnosis of HCC in patients with liver cirrhosis and a focal hypervasular liver lesion (>2 cm) in at least one imaging technique. Patients with potentially resectable liver mass and AFP >400 ng/ml should undergo surgery without preoperative FNAC or biopsy.
staging and risk assessment
Staging should include X-ray of chest and CT scan of the abdomen. Tumors should be staged according to AJCC staging criteria/TNM system. The fibrolamellar variant is not associated with cirrhosis and has a more favorable prognosis.
Staging systems such as CLIP or BCLC that include staging of liver cirrhosis may improve prediction of the ultimate prognosis of HCC patients. Risk assessment is based on Pugh's modification of Child's grading of liver function. For patients being considered for liver transplantation, MELD score is also useful.
Child-Pugh grade C patients should be offered only supportive care. Child-Pugh grade A and favorable grade B should be evaluated for specific treatment options.
treatment plan
This should be based on extent of disease, growth pattern of tumor, hepatic functional reserve and patient's performance status. Chemoembolization for patients with adequate hepatic functional reserve and multifocal HCC. Percutaneous ethanol injection for patients with fewer than three or four tumor nodules, maximum 5 cm in size. Radiofrequency ablation also for tumors <5 cm in size and/or fewer than four in number. Inclusion in clinical trials. Best supportive care. Systemic chemotherapy containing anthracyclines, cisplatin and 5-FU with a prospect of a 10% response rate and no survival benefit (if bilirubin normal and hepatic reserve adequate).
In a phase II study Sorafenib induced response in 8% and disease control in 41% of patients. In a phase III study it extended survival for 2.8 months. 
follow-up
Patients undergoing curative resection should be followed up 3-to 6-monthly with AFP determination and liver imaging (for 2 years)-since curative therapy can still be offered at relapse, to a minority. The indications for antiviral/IFN therapy for patients positive for hepatitis C and hepatitis B virus should depend on the degree of hepatitis and/or liver cirrhosis and viral replicative status. For other patients, follow-up aims to prevent and/or treat hepatic decompensation. A total score of 5-6 is considered grade A (well-compensated disease); 7-9 is grade B (significant functional compromise); and 10-15 is grade C (descompensated disease).
